Predictive Value of IL28B Gene Polymorphism Combined with Pretreatment Serum IP-10 Quantification for Response to Peginterferon and Ribavirin Is Enhanced in Comparison with any of these Biomarkers alone
The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.
1 . Method of combining two or more parameters selected from the group consisting of the pre-treatment serum level measurement of IP-10, the IL28B genotype determination, race or Hepatitis C viral load determination to predict the outcome of sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.
2 . Method according to claim 1 wherein said IL28B genotype determination with said pre-treatment serum level measurement of IP-10 is combined to predict the outcome of sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.
3 . Method according to claim 2 wherein the race parameter is added.
4 . Method according to claim 2 wherein the Hepatitis C viral load determination is added.
5 . Method according to claim 2 wherein the race parameter and the Hepatitis C viral load determination are added.
6 . Method according to any of the claims 1 - 5 wherein the IL28B genotype comprises the polymorphic marker rs12979860, rs12980275 and/or rs8099917, or any other genetic marker that is in linkage disequilibrium with these markers.
7 . Method according to claim 6 wherein the combination measurement further discriminates between SVR and non-response to peginterferon and ribavirin for an individual patient infected with HCV, in comparison with any of these two individual markers (IL28B genotype, serum IP-10 level).
8 . Diagnostic assay for use in the method according to any of the claims 1 - 7 comprising means for at least the determination or measurement of IL28B polymorphism and IP-10 levels in serum from an HCV-infected patient.
9 . Computer system comprising modeling software using the outcome information obtained from the method of any of the claims 1 - 7 for the prediction of sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.